VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 336 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2017. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $10,000 | +150.0% | 500 | +100.0% | 0.02% | +242.9% |
| Q3 2017 | $4,000 | 0.0% | 250 | 0.0% | 0.01% | +16.7% |
| Q2 2017 | $4,000 | – | 250 | +861.5% | 0.01% | – |
| Q1 2017 | $0 | -100.0% | 26 | -90.6% | 0.00% | -100.0% |
| Q4 2016 | $4,000 | -60.0% | 276 | -31.2% | 0.01% | -61.1% |
| Q3 2016 | $10,000 | +900.0% | 401 | +1442.3% | 0.02% | +800.0% |
| Q2 2016 | $1,000 | -50.0% | 26 | -71.1% | 0.00% | -33.3% |
| Q1 2016 | $2,000 | -71.4% | 90 | +32.4% | 0.00% | -70.0% |
| Q4 2015 | $7,000 | +40.0% | 68 | +134.5% | 0.01% | +42.9% |
| Q3 2015 | $5,000 | -97.1% | 29 | -96.3% | 0.01% | -96.5% |
| Q2 2015 | $173,000 | +11.6% | 777 | -0.1% | 0.20% | +7.0% |
| Q1 2015 | $155,000 | +38.4% | 778 | -0.8% | 0.19% | +43.1% |
| Q4 2014 | $112,000 | +1.8% | 784 | -6.2% | 0.13% | -8.5% |
| Q3 2014 | $110,000 | -77.2% | 836 | -79.6% | 0.14% | -80.5% |
| Q4 2013 | $482,000 | – | 4,103 | – | 0.73% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |